IL17A and myeloid sarcoma: TRAF3 is part of other annotated pathways, such as NOD-like receptor signaling, RIG-I-like receptor signaling, IL-17 signaling, and TNF signaling, all known to be altered in autoimmune diseases and MS development (35, –37).